Previous studies in MET-driven non-small cell lung cancer (NSCLC) linked MET exon 14-alterations with crizotinib sensitivity, while phosphoinositide 3-kinase (PI3K) pathway alterations correlated with a worse response to MET inhibition [7,8]. Here, MET is linked to non-small cell lung carcinoma.